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endothelial cells: A link to atherosclerosis in patients with
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Carbamylated low-density lipoprotein induces death of en-
dothelial cells: A link to atherosclerosis in patients with kidney
disease.
Background. The presence of accelerated atherosclerosis
in patients with kidney disease cannot be entirely explained
by traditional cardiovascular risk factors. Exposure to urea,
which is normally present in human blood plasma and ele-
vated in patients with kidney disease, leads to the carbamy-
lation of proteins. We postulated that low-density lipoprotein
(LDL) carbamylated by urea has biologic effects relevant to
atherosclerosis.
Methods. To produce carbamylated LDL (cLDL), human na-
tive LDL (nLDL) was chemically modified in vitro by expo-
sure to potassium cyanate. Human coronary artery endothelial
cells (HCAECs) and human coronary artery smooth muscle
cells (CASMCs) were treated in vitro with cLDL or nLDL.
Irreversible cell death was measured using the lactate dehy-
drogenase (LDH) assay, apoptosis was assessed by annexin V
binding, and proliferation was determined using bromod-
eoxyuridine (BrdU) incorporation. Total plasma protein car-
bamylation and plasma cLDL were measured in hemodialysis
patients using the homocitrulline assay and enzyme-linked im-
munosorbent assay (ELISA).
Results. Our studies demonstrated that cLDL but not nLDL
induced dose-dependent vascular cell injuries relevant to
atherosclerosis, which included the proliferation of vascular
smooth muscle cells and endothelial cell death. Under light mi-
croscopy, endothelial cells treated with cLDL showed signs of
morphologic alterations. The injury to endothelial cells mea-
sured by LDH release was time-dependent and correlated with
the degree of LDL carbamylation. At least a part of the en-
dothelial cell population treated with cLDL died by apoptosis.
In patients with advanced renal disease on hemodialysis, total
plasma protein carbamylation and plasma cLDL were several
times higher than in control healthy individuals.
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Conclusion. Collectively these data suggest the potential role
of carbamylated LDL in accelerated atherosclerosis in patients
with chronic renal disease and, possibly, in healthy individuals.
Chronic kidney disease is a worldwide medical and
public health problem that is beginning to assume epi-
demic proportions. Chronic kidney disease, which can re-
sult from a wide variety of disorders (including diabetes,
hypertension, and glomerulonephritis) is a common dis-
order affecting about 10% of the worldwide population
[1–3]. A large body of evidence indicates that kidney dis-
ease is an independent risk factor for the development
of cardiovascular disease [4]. Cardiovascular disease is a
leading cause of death in patients with chronic renal in-
sufficiency. After stratification for age, gender, race, and
the presence or absence of diabetes, the cardiovascular
mortality in patients with advanced kidney disease is 10 to
20 times greater than in the general population [4]. The
increased prevalence of coronary artery disease in pa-
tients with kidney disease cannot be explained entirely
by traditional cardiovascular risk factors.
Carbamylation is a protein modification induced by
urea-derived cyanate normally present in human blood
plasma and elevated in patients with chronic kidney dis-
ease [5]. We postulated that in patients with renal dis-
ease, carbamylation of low-density lipoprotein (LDL) is
a nontraditional risk factor for cardiovascular disease. In
order to obtain support for this hypothesis, we exam-
ined whether carbamylated LDL (cLDL) has biologic
effects that are relevant to atherosclerosis. It is com-
monly accepted that endothelial cell injury is an initial
event in atherosclerosis [6, 7]. Injured endothelial cells
attract monocytes, which burrow beneath the endothelial
cell layer and ingest modified LDL to form “foam cells”
[8]. This process leads to the formation of atherosclerotic
plaque (consisting of “foam cells” and macrophages cov-
ered by a fibrous cap) which protrudes into the vessel
173
174 Ok et al: Endothelial cell death induced by carbamylated LDL
lumen over the proliferating vascular smooth muscle cells
[8].
In the present study, we tested the atherosclerosis-
prone effects of chemically cLDL: the ability to cause
death of cultured human coronary artery endothelial cells
(HCAECs) and induce proliferation of human vascular
smooth muscle cells in vitro. In addition, we studied total
plasma protein carbamylation and cLDL level in end-
stage renal disease (ESRD) patients receiving hemodial-
ysis in comparison to the control group of healthy
individuals.
METHODS
LDL isoforms
Native human LDL (nLDL) was purchased from Fluka
(Milwaukee, WI, USA). cLDL was prepared as described
by Weisgraber, Innerarity, and Mahley [9]. Sterile potas-
sium cyanate (KOCN) (Aldrich, Milwaukee, WI, USA)
was added to the lipoprotein solution at 20 mg/mg LDL
protein. The mixture was incubated at 35◦C for 4 hours.
KOCN was removed by excessive dialysis under ster-
ile conditions at 4◦C against 0.15 mol/L NaCl, 0.01%
ethylenediaminetetraacetic acid (EDTA), pH 7.0, for
36 hours. About 5 mL of the LDL preparation was
dialyzed against 5 L buffer, which was changed every
12 hours. The concentration of potassium cyanate after
the first dialysis was 3.7 mmol/L and could not be detected
after second or third dialyses using Dimension RxL an-
alyzer (Dade Behring, Deerfield, IL, USA). At this con-
centration, KOCN did not have any cytotoxic effect on
the endothelial cells. In addition, used buffer after the
second or third dialyses did not have any effect in control
experiments. cLDL was kept at 4◦C, away from light and
used within 2 weeks after preparation.
Lipoprotein electrophoresis
The electrophoretic mobility of nLDL and modi-
fied LDLs was determined by electrophoresis on 0.5%
agarose gel in 50 mmol/L sodium barbital buffer, pH 8.6,
as described by Noble [10]. After applying the samples
(7 lg LDL protein per well), electrophoresis was run at
12 V/cm for 1 hour. The gel was fixed in ethanol-acetic
acid-water mixture (60:10:30, vol:vol:vol) and stained in
0.2% Sudan Black B dissolved in 60% ethanol. The rel-
ative electrophoretic mobility (REM) was expressed as
the ratio of the mobility of a modified LDL to that of the
nLDL.
Assessment of carbamylation
A colorimetric method using diacetyl monoxime [11]
was used to measure the degree of carbamylation in LDL
preparations. Briefly, the LDL suspension (25 lg of pro-
tein) was digested in 50 lL phosphate-buffered saline
(PBS), pH 7.4, 1% sodium dodecyl sulfate (SDS) with
2 lg proteinase K at 37◦C for 2 hours. Then 250 lL
of urea-nitrogen reagent (0.83 mol/L sulfuric acid, 1.13
mol/L orthophosphoric acid, 0.55 mmol/L thiosemicar-
bazide, and 2.6 mmol/L cadmium sulfate) and 50 lL
diacetyl monoxime were added to the reaction mix-
ture and the incubation continued at 97◦C for 30 min-
utes. Precipitate was removed by centrifugation at 3500g
for 10 minutes at room temperature. The supernatant
(200 lL) was transferred into a 96-well plate and absorp-
tion was measured at 530 nm. A standard curve was gener-
ated using homocitrulline (e-amino-carbamyllysine, 0 to
30 nmol) (Advanced Asymmetrics, Millstadt, IL, USA).
The results were expressed in nmol homocitrulline/mg
LDL protein.
Assessment of oxidation
Oxidation of LDL was evaluated using the thiobar-
bituric acid reactive substances (TBARS) assay [12].
Freshly prepared 1,1,3,3-tetramethoxypropane, which
yields malondialdehyde (MDA), was used as a stan-
dard. The results were expressed in nmol MDA/mg LDL
protein.
Cell cultures
HCAECs and human coronary artery smooth mus-
cle cells (CASMCs) were obtained from Clonetics
(Walkersville, MD, USA) and used at passages between
4 and 8. HCAECs and CASMCs were maintained in en-
dothelial growth medium microvasculature (EGM-MV)
or smooth muscle growth medium-2 (SmGM-2) (Cam-
brex, Baltimore, MD, USA), respectively, supplemented
with growth factors and 5% fetal bovine serum (FBS).
Cells were grown in a humidified incubator (5% CO2,
37◦C) and were treated with 50 to 400 lg/mL LDL iso-
forms in serum-free EGM-MV medium for 2 to 24 hours.
Control cells were treated with PBS for the same period
of time.
Cytotoxicity assays
After exposure to LDL isoforms, a lactate dehydroge-
nase (LDH) release assay kit (Promega, Madison, WI,
USA) was used to measure cytotoxicity. The latter was
expressed as the ratio of LDH released by treated cells
into medium to the total LDH. Trypan blue exclusion was
measured in combined attached and floating cells using
the previously described procedure [13].
Annexin V binding
HCAECs were treated with 200 lg/mL LDL isoforms
for 16 hours in serum-free medium, and floating and
attached cells were collected by centrifugation at 200g.
Cell suspension was stained using ApoAlert Annexin
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V Apoptosis Kit (Clontech, Palo Alto, CA, USA) and
analyzed in a Becton Dickinson FACScan flow cytome-
ter (San Jose, CA, USA).
Bromodeoxyuridine (BrdU) assay
The BrdU cell proliferation assay (Oncogene, Cam-
bridge, MA, USA) was used to identify cells in the S
phase of the cell cycle. CASMCs were seeded into a
96-well plate (3.5 × 103 cells/well) and grown overnight
in SmBM medium with 5% FBS. The cells were rinsed
once with serum-free medium and then exposed to 0 to
200 lg/mL LDL isoforms in serum-free medium. One
hour prior to the end of the experiment the BrdU label
was added. Cells were fixed, denatured, and probed with
anti-BrdU antibody as suggested by the manufacturer’s
manual.
Protein measurement
Protein was measured using the BCA Protein As-
say (Pierce, Rockford, IL, USA). Bovine serum albumin
(BSA) was used as the standard.
Human subjects
Written informed consent was obtained from all pa-
tients and control subjects. The consent form and study
design were approved by the University of Arkansas for
Medical Sciences/Central Arkansas Veterans Healthcare
System Institutional Review Board. Blood samples were
obtained from 13 hemodialysis patients and 11 healthy
subjects. In patients, the blood was collected immediately
before dialysis. The groups were matched by age (48.2 ±
4.6 and 59.7 ± 3.9 in patients and control group, respec-
tively) (P > 0.1) and gender (seven males and six females
among patients, six males and five females in the control
group) (P > 0.9) and had no significant difference by all
used criteria, including body weight, smoking habit, dia-
betes, cardiovascular diseases, cholesterol, triglycerides,
and others.
Enzyme-linked immunosorbent assay (ELISA)
detection of cLDL
Antibody to cLDL was raised in rabbits and puri-
fied by affinity chromatography until they had no cross-
reactivity with nLDL in ELISA or Western blotting (data
not shown). Measurement of cLDL in fasting serum col-
lected before dialysis using ELISA was performed ac-
cording to the protocol described by Lorec et al [14], with
the exception that anti-cLDL was used as primary anti-
body. Serum was used in a dilution 1:200. All measure-
ments were performed in quadruplicating format.
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Fig. 1. Characterization of chemically prepared carbamylated low-
density lipoprotein (cLDL). (A) Mobility of cLDL (visualized by a Su-
dan Black staining) in agarose gel is increased compared to native LDL
(nLDL). (B) In vitro cLDL has increase portion of homocitrulline (car-
bamyl lysine), but is not oxidized as measured by the malondialdehyde
(MDA) content.
Statistical analysis
Statistical analysis was performed with analysis of vari-
ance (ANOVA) and Student t test. Results were ex-
pressed as mean ± standard error of the mean (SEM).
RESULTS
Characterization of LDL isoforms
During carbamylation, urea undergoes a spontaneous
nonenzymatic transformation to cyanate, the active form
of which, isocyanic acid, reacts with free nonprotonated
amino groups of proteins. Carbamylation results in neu-
tralization of the positive charge of the modified ly-
sine and enhances the mobility of the LDL in agarose
[5]. In our experiments, the electrophoretic mobility of
cLDL was accelerated after carbamylation of nLDL
with KOCN (Fig. 1A). The degree of carbamylation
was assessed by measurement of homocitrulline, which
indicated that after 6 hours of carbamylation, cLDL con-
tained 221 ± 16 homocitrulline nmol/mg LDL protein,
compared to 5 ± 1 nmol/mg protein in nLDL (Fig. 1B).
Importantly, spontaneous oxidation did not occur during
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Fig. 2. Morphologic changes and cell death
induced in human coronary artery endothe-
lial cells (HCAECs) by carbamylated low-
density lipoprotein (cLDL). Cells treated with
200 lg/mL cLDL show morphologic signs of
deterioration compared to cells treated with
the same amount of native LDL (nLDL) (up-
per panels). The cells are smaller than nor-
mal, shrunken, and some of them are de-
tached from the plate. The monolayer is dis-
rupted (areas of cell-free surface shown by
arrows). Spaces between cells are filled with
cellular debris. Treatment of endothelial cells
with cLDL, but not nLDL induced cell death
measured by lactate dehydrogenase (LDH)
release (lower panels).
carbamylation, as indicated by a low content of MDA
in both nLDL (0.9 ± 0.3 nmol MDA/mg LDL protein)
and in cLDL (0.7 ± 0.3 nmol MDA/mg LDL protein),
thus providing us with the specific LDL isoforms for the
experiments.
Assessment of cLDL cytotoxicity
To assess cytotoxicity of cLDL, cultured HCAECs
were treated with 50 to 400 lg/mL LDL isoforms for up
to 24 hours. Under light microscopy, cells treated with
nLDL looked unaffected (Fig. 2). To the contrary, cells
treated with cLDL showed signs of morphologic alter-
ations and the presence of cellular debris. Many of the
cells shrunk and detached from the plastic (Fig. 2).
LDH release assay was applied to assess irreversible
cell injury. This assay showed that cLDL, but not nLDL,
induced the increased release of LDH into the culture
medium. At 200 lg/mL, cytotoxicity was 20 ± 2% with
cLDL compared to 7 ± 1% induced by nLDL (Fig. 2).
To further characterize the cytotoxicity, cultured
HCAECs were treated with 200 lg/mL LDL isoforms
for a period of 2, 4, 8, 12, or 24 hours. The injury mea-
sured by LDH release was dose- and time-dependent,
and correlated with the degree of LDL carbamylation
(Fig. 3). Cytotoxicity measured using trypan blue exclu-
sion in combined attached and floating cells was higher
in the cell population treated with cLDL than with nLDL
(9 ± 2% vs. 3 ± 2%, respectively). Total cell number was
decreased 10% after 200 lg/mL cLDL treatment, while
the same concentration of nLDL did not induce the re-
duction of cell number.
We also examined the ability of cLDL to induce apop-
tosis. For this we utilized the annexin V assay, which is
based on the binding of annexin V to phosphatidylser-
ine and provides a simple and accepted method to
detect apoptosis at a very early stage. Fluorescence-
activated cell sorting (FACS) analysis of cells stained with
fluorescein-conjugated annexin V and propidium iodide
was applied. It showed that endothelial cells exposed to
cLDL revealed a higher percentage of apoptotic cells (an-
nexin V+/propidium iodide−) than nLDL (24 ± 4% vs. 14
± 3%) (P < 0.01) (Fig. 4). No significant change in the per-
centage of necrotic cells (annexin V−/propidium iodide+
plus annexin V+/propidium iodide+) was observed (35 ±
5% vs. 33 ± 4%) (P < 0.05).
Induction of vascular smooth muscle cell proliferation
by cLDL
The proliferation of vascular smooth muscle cells is
an important component of atherogenesis, contributing
to narrowing of the vessel lumen [8]. We examined the
ability of cLDL to induce proliferation of cultured hu-
man CASMCs utilizing BrdU incorporation into newly
synthesized DNA. Our experiments demonstrated that
although nLDL induced some CASMCs proliferation,
cLDL induced proliferation of these cells several times
higher at all used concentrations (Fig. 5). The effect of
cLDL on CASMC proliferation was dose-dependent.
Measurement of cLDL in hemodialysis patients
As an approach to examine the relevance of LDL car-
bamylation to the increased incidence of atherosclerosis
in patients with kidney disease, total plasma protein car-
bamylation was measured by homocitrulline assay and
plasma cLDL was assayed by ELISA using antihuman
cLDL. Our data showed that patients with advanced re-
nal failure receiving hemodialysis treatment had signif-
icantly elevated level of protein carbamylation to 42 ±
4 nmol homocitrulline/mg protein (N = 13) above the
control group level of 12 ± 3 nmol homocitrulline/mg
protein (N = 11) (P < 0.01) (Fig. 6A). In good corre-
lation with this observation, cLDL measured by ELISA
was increased in hemodialysis patients to 0.352 ± 0.051
from the control level of 0.096 ± 0.030 (P < 0.001)
(Fig. 6B).
DISCUSSION
Based on studies of oxidized LDL (oxLDL) and LDL
with other modifications, it is commonly accepted that en-
dothelial cell injury by modified LDLs is an initial event
in atherosclerosis [6, 7]. Although different modified
LDLs were found in uremic patients [15, 16], and oxLDL
was shown to be elevated in uremic patients [17–19], no
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Fig. 3. Carbamylated low-density lipopro-
tein (cLDL)-induced human coronary artery
endothelial cell (HCAEC) death is depen-
dent on the degree of carbamylation and the
time of exposure with cLDL. (A) Native LDL
was carbamylated to different degrees as de-
scribed in the Methods section by varying the
time of the exposure with potassium cyanate,
which was then removed by excessive dialy-
sis. HCAECs were exposed with the result-
ing cLDL (200 lg/mL) for 24 hours and cell
death was measured by lactate dehydrogenase
(LDH) release. (B) Time course of cLDL (200
lg/mL) treatment of HCAECs. Cell death was
assessed by LDH release.
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Fig. 4. Apoptosis of human coronary artery endothelial cells
(HCAECs) induced by carbamylated low-density lipoprotein (cLDL).
Cells were treated with 200 lg/mL LDL isoforms for 16 hours and apop-
tosis was measured using annexin V/propidium iodide staining. The
number of apoptotic cells (AV+/PI−) was detected by fluorescence-
activated cell sorting (FACS) analysis. Each point is the mean ± SEM
for N = 4 to 6. ∗P < 0.01. nLDL is native low-density lipoprotein.
mechanistic studies to establish a cause-effect relation-
ship between oxLDL or another modified LDL and
atherosclerosis during uremia were performed.
Urea is a normal component of human blood plasma
where it undergoes spontaneous transformation to
cyanate. With the decrease of renal function, there is an
increased amount of urea, and cyanate acts as a uremic
toxin through the carbamylation of proteins [5]. Cyanate
can react irreversibly with the free epsilon amino groups
of lysine and N-terminal amino acids within proteins. The
resulting in vivo carbamylation can change the structure
of proteins [20, 21], and modify the activity of enzymes,
cofactors, hormones, and antibodies [5, 22].
cLDL was shown to interact with cell surface receptors
in human fibroblasts and prevent the binding of nLDL in
human fibroblasts [9]. LDL isolated from uremic patients
as well as chemically modified cLDL had a slower clear-
ance from plasma in rabbits than LDL from normal sub-
jects or nonmodified LDL [23, 24]. The effects of cLDL
on endothelial cells have not been previously studied.
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Fig. 5. Dose-dependent induction of human coronary artery vascu-
lar smooth muscle cell (CASMC) proliferation by carbamylated low-
density lipoprotein (cLDL). CASMCs were cultured and treated with
cLDL or native LDH (nLDL) and proliferation was measured by bro-
modeoxyuridine (BrdU) assay as described in the Methods section.
Our data indicate that human cLDL induces injury to en-
dothelial cells in vitro, as measured both by LDH release
(irreversible cell death) and by annexin V binding (apop-
tosis). We showed that human cLDL also induced prolif-
eration of vascular smooth muscle cells, which is usually
associated with a proatherosclerotic action of modified
LDL [25].
The combination of in vitro studies demonstrating
the ability of cLDL to have biologic effects relevant
to atherosclerosis (endothelial cell injury and vascular
smooth muscle proliferation), along with elevated cLDL
in hemodialysis patients, suggests an important role of
LDL carbamylation in atherosclerosis observed in ESRD
patients.
It must be emphasized that although we have studied
only patients with ESRD, it is very likely that patients with
moderate renal insufficiency would also have increased
cLDL. Because urea is present in normal plasma, it can
be hypothesized that these data can be applied not only to
renal patients but also to normal individuals. It is yet to be
determined whether and how cLDL may be involved in
the development of atherosclerosis by other mechanisms
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Fig. 6. Increase of total plasma protein car-
bamylation and plasma carbamylated low-
density lipoprotein (cLDL) concentration in
end-stage renal disease (ESRD) patients on
hemodialysis. (A) Plasma protein carbamy-
lation was measured by homocitrulline as-
say as described in the Methods section in
a group of control individuals (N = 11) and
a group of ESRD patients on hemodialysis
(N = 13). ∗P < 0.01. (B) cLDL was deter-
mined using enzyme-linked immunosorbent
assay (ELISA) in the same groups. Results are
given as absorbance at 450 nm. ∗∗P < 0.001.
(e.g., endothelial cell dysfunction, expression of adhesion
molecules, increase of monocyte adhesion to endothelial
cells, increase of procoagulant activity). Further studies
are required to identify the specific signaling pathway
for apoptosis and receptor(s) for cLDL. Future attempts
to prevent LDL carbamylation and/or reduce the effects
of carbamylation may provide novel treatments for the
prevention of atherosclerosis.
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